Business Wire

Takeda Selects Two New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Support Strong Health Systems and Access to Healthcare in Developing Countries

11.6.2020 09:00:00 EEST | Business Wire | Press release

Share

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced the addition of two partners to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare systems and improve access to healthcare for all in developing countries. As part of an annual decision-making process, Takeda employees worldwide have voted to add the Access to Health Fund and Bridges to Development as new partners for the Global CSR Program, which now supports 16 programs in more than 60 countries.

Takeda’s commitments to these new partner organizations in FY2020 include:

  • JPY 1.1 billion (USD 10.1 million*) to Access to Health Fund to help build and improve community health centers and empower health staff from ethnic health organizations and ethnic community-based health organizations (EHOs/ECBHOs) in Myanmar’s Shan State to deliver quality health services, particularly for mothers and children, over the next 5 years.
  • JPY 681 million (USD 6.3 million*) to Bridges to Development to eliminate or control 5 neglected tropical diseases in Papua New Guinea and Vanuatu including lymphatic filariasis, yaws, leprosy, trachoma, and soil-transmitted helminthiases. The 3-year project will improve health worker capacity, access to care and treatment.

“We welcome and very much value the interest that Takeda and its employees have shown in contributing to improving the health of vulnerable populations in conflict-affected and hard-to-reach areas in Shan State in Myanmar,” said Oren Ginzburg, Access to Health Fund Director.

“The Bridges team is thrilled to embark on this important work in service of communities and populations that have been frequently left behind,” said Julie Jacobson, Managing Partner & Co-Founder of Bridges to Development. “In this project, working with countries, we aim to achieve lasting health benefits through the elimination and control of several neglected tropical diseases in one innovative approach. We are thankful to Takeda employees who helped make this possible with their support.”

This year represents the 5th anniversary of Takeda’s Global CSR Program, which empowers employees in Takeda’s 80 countries of operation to be the decisionmakers for which innovative, high-impact activities receive the Company’s support. The Program, rooted in the company’s values, actively partners with world-class organizations and nongovernmental organizations (NGOs) with proven track records of addressing global health problems in effective, enduring ways to prevent disease, train health workers, strengthen supply chains, and improve access to quality diagnosis and treatment for patients worldwide.

“Since its launch in 2016, Takeda’s Global CSR Program has focused on initiatives that strengthen health systems and increase access across the patient journey in low- and middle-income countries. We’re expecting to reach at least 17 million beneficiaries through 2025 globally” said Takako Ohyabu, Chief Global Corporate Affairs Officer. “We are proud to partner with the Access to Health Fund and Bridges to Development as we strive to increase health worker capacity and preventive care for patients everywhere, ensure reliable access to essential equipment and supplies, and empower communities with knowledge, services, and access to care."

In less than five years, Takeda’s Global CSR Program partners have delivered transformational impact that serves communities worldwide today and will continue to contribute to better health outcomes and stronger health systems for years to come, including:

  • JOICFP, Plan International, and UNICEF reached nearly 700,000 pregnant women and mothers, newborns, children, and adolescents, with quality health care, services, and education in sub-Saharan Africa and the Middle East.
  • JOICFP, Plan International, Seed Global Health, and UNICEF in Africa and the Middle East, with World Vision in South Asia, have collectively trained approximately 6,000 health workers in 15 countries, including qualified nurses, midwives, and physician trainees, as well as community health workers and nutrition volunteers.
  • Millions of children have been immunized against measles, and the capacity of trainings offered by academic and clinical institutions in sub-Saharan Africa has been expanded exponentially.

In line with Takeda’s core values and longstanding support for strong health systems and access to healthcare for all, Takeda recently announced contributions to the global COVID-19 response through three United Nations-led organizations to strengthen health systems, improve access to care and supplies, and address food insecurity.

Takeda also forges farsighted public-private philanthropic partnerships with game-changing multilateral and academic institutions worldwide, such as with The Global Fund to Fight AIDS, Tuberculosis and Malaria, and the London School of Hygiene & Tropical Medicine.

* Financial information relating to the donations has been converted from JPY to USD using the ¥108.87:$1 as of June 3, 2020. For the avoidance of doubt, the amounts payable as part of the donations are denominated in JPY.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Takeda Pharmaceutical Company Limited
Ai Yoshikawa
+81(0)3-3278-3004
ai.yoshikawa@takeda.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FuzeBox AI Named Founding Co-Author of SPUR Coalition Technical Committee on Verifying AI Content Use5.10.2026 16:00:00 EEST | Press release

FuzeBox AI has been named by the SPUR Coalition, an international nonprofit of 37 news and media organizations, as one of four founding co-authors of its Evidence Profile Technical Committee, adopted Sept. 2, 2026, to draft an evidence profile for SPUR's Content Telemetry standard: a way for publishers to verify AI usage reports without depending on the reporting company's cooperation. Under SPUR's current standard, AI companies self-report their content use. A company that skips reporting leaves no record, and publishers can't check what they do receive. On July 10, 2026, FuzeBox proposed its Verified Provenance Telemetry Standard (VPTS): publishers seed content with detectable markers, then verify their appearance in AI outputs via an auditable ledger, with no change to SPUR's standard. Within 48 hours, three organizations filed related proposals: ProRata on usage magnitude, Encypher CEO Erik Svilich on the verification question FuzeBox raised, and LicenseFoundry on portable proof of

Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 15:02:00 EEST | Press release

Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty Texture Editwas designed to resonate with a global cultural beauty movement captivating the next gene

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 15:00:00 EEST | Press release

GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005273717/en/ SOFIE Biosciences has 15 CMO sites across the U.S., manufacturing PET radiopharmaceutical products The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics

Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 14:24:00 EEST | Press release

Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking expertise with Solos' proprietary dealcoholization and patented aroma recovery technology. With 30 years of experience in producing alcohol-free sparkling wines, Henkell Fre

Croma-Pharma Expands Its Portfolio in Canada With saypha ® lips Lidocaine and Exprecell™5.10.2026 14:12:00 EEST | Press release

Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye